

AMENDMENT TO RULES COMMITTEE

PRINT 117-31

OFFERED BY MR. STAUBER OF MINNESOTA

At the end of division E, add the following:

1 **SEC. 40103. REQUIREMENT TO PURCHASE PHARMA-**
2 **CEUTICALS FROM THE UNITED STATES.**

3 (a) IN GENERAL.—Except as provided in subsection
4 (b), the head of an executive agency may only purchase
5 a covered drug if the drug is over 50-percent sourced,
6 manufactured, and assembled in the United States.

7 (b) EXCEPTION.—The head of an executive agency
8 may waive the requirement of subsection (a)—

9 (1) if the covered drug is not available in suffi-
10 cient quantity or quality as over 50-percent sourced,
11 manufactured, and assembled in the United States;
12 or

13 (2) during an emergency period (as defined in
14 section 1135(g)(1)(A) of the Social Security Act (42
15 U.S.C. 1320b-5(g)(1)(A))).

16 (c) MODIFICATIONS TO TRADE AGREEMENTS.—

17 (1) IN GENERAL.—Not later than 30 days after
18 the date of the enactment of this Act, the United
19 States Trade Representative shall modify United

1 States product coverage under all free trade agree-
2 ments and the World Trade Organization Agreement
3 on Government Procurement to exclude coverage of
4 essential medicines and medical countermeasures.

5 (2) MODIFICATION OF WAIVERS.—Subsequent
6 to the modifications made under paragraph (1), the
7 United States Trade Representative shall make any
8 necessary corresponding modifications of existing
9 waivers under section 301 of the Trade Agreements
10 Act of 1979 (19 U.S.C. 2511).

11 (3) NOTIFICATION TO THE PRESIDENT.—Sub-
12 sequent to the modifications made under paragraphs
13 (1) or (2), the United States Trade Representative
14 shall notify the Director of the Office of Manage-
15 ment and Budget.

16 (d) DEFINITIONS.—In this section:

17 (1) COVERED DRUG.—The term “covered drug”
18 means a drug (including the active pharmaceutical
19 ingredients thereof) marketed in the United States
20 pursuant to an approval or licensure under sub-
21 section (c) or (j) of section 505 of the Federal Food,
22 Drug, and Cosmetic Act (21 U.S.C. 355) or under
23 subsection (a) or (k) of section 351 of the Public
24 Health Service Act (42 U.S.C. 262).

1 (2) EXECUTIVE AGENCY.—The term “executive
2 agency” has the meaning given that term in section
3 133 of title 41, United States Code.

4 (3) UNITED STATES.—The term “United
5 States” means each of the several States, the Dis-
6 trict of Columbia, and each territory or possession of
7 the United States.

8 (e) SEVERABILITY CLAUSE.—If any provision of this
9 section (or the application of that provision to particular
10 persons or circumstances) is held invalid, the remainder
11 of this section (or the application of that provision to other
12 persons or circumstances) shall not be affected.

13 (f) EFFECTIVE DATE.—The provisions of this section
14 shall apply beginning on the date that is one year after
15 the last day of the emergency period (as defined in para-
16 graph (1)(B) of section 1135(g) of the Social Security Act
17 (42 U.S.C. 1320b–5(g)).

